resTORbio, Inc. Company Profile

22:19 EDT 21st September 2019 | BioPortfolio

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caused by immunosenescence, the decline in immune function that occurs during aging. resTORbio’s lead product candidate, RTB101, is in a Phase 2b clinical trial to evaluate its potential in reducing the incidence of respiratory tract infections (RTI) in elderly subjects at increased risk of RTI-related morbidity and mortality. resTORbio’s lead program is supported by two Phase 2a clinical studies from which promising safety and efficacy signals were observed in almost 500 hundred elderly subjects. resTORbio is pursuing a pragmatic clinical development plan to address areas of key unmet medical need in the aging population. For more information, please visit resTORbio is an affiliate of PureTech Health.

News Articles [31 Associated News Articles listed on BioPortfolio]

Klickstein Leaves NIBR for resTORbio Chief Scientific Officer Role

Lloyd Klickstein has joined resTORbio (NASDAQ: TORC) as chief scientific officer. Klickstein comes to Boston-based resTORbio from the Novartis Institutes for Biomedical Research (NIBR), where was glob...

resTORbio Announces Closing Public Offering of Common Stock

resTORbio (NASDAQ:TORC) has announced the closing of a previously announced underwritten public offering of 7.2 million shares of its common stock at a price of US$6.95 per share. As quoted in the pre...

resTORbio launches trial of RTB101 to treat Parkinson’s

US-based biopharmaceutical firm resTORbio has commenced a Phase Ib/IIa clinical trial of its RTB101 candidate as a monotherapy or combination...Read More... The post resTORbio launches trial of RTB101...

resTORbio launches Phase III respiratory illness programme

resTORbio has commenced the Phase III PROTECTOR clinical programme to assess RTB101 to treat clinically symptomatic respiratory illness in elderly...Read More... The post resTORbio launches Phase III ...

FOPO nets $47mm for resTORbio

ResTORbio Inc. (developing therapies to prevent or treat age-related diseases) netted $47mm through the follow-on public offering of 7.2mm common shares at $6.95 each. The company will use some of the...

resTORbio Completes Early Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101

resTORbio (NASDAQ:TORC) has announced it has finished enrolling patients in the Phase 3 PROTECTOR 1 trial ahead of schedule. As quoted in the press release: PROTECTOR 1 is the first of two global Phas...

An Interview with Dr. Joan Mannick of resTORbio

resTORbio Announces Phase 3 Human Trials

Last year, resTORbio announced the positive results of its phase 2b hum

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

resTORbio, Inc.

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. r...

More Information about "resTORbio, Inc." on BioPortfolio

We have published hundreds of resTORbio, Inc. news stories on BioPortfolio along with dozens of resTORbio, Inc. Clinical Trials and PubMed Articles about resTORbio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of resTORbio, Inc. Companies in our database. You can also find out about relevant resTORbio, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record